Human Growth Hormone (HGH) vs Survodutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Human Growth Hormone (HGH)
Human Growth Hormone (somatropin) is a 191-amino acid protein identical to naturally produced GH. FDA-approved for growth hormone deficiency, Turner syndrome, and other conditions. Widely used off-label for anti-aging and performance.
Full details →Survodutide
Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. It is being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and obesity. Survodutide's glucagon receptor activation promotes hepatic fat mobilization, making it uniquely suited for liver-related metabolic conditions.
Full details →Side-by-Side Comparison
| Aspect | Human Growth Hormone (HGH) | Survodutide |
|---|---|---|
| Mechanism | Binds to GH receptors throughout the body, stimulating IGF-1 production in the liver. Promotes protein synthesis, fat metabolism, and cellular regeneration across multiple tissues. | Survodutide activates both GLP-1 and glucagon receptors. The GLP-1 component provides appetite suppression, glucose-dependent insulin secretion, and delayed gastric emptying. The glucagon component drives hepatic fat oxidation, increases energy expenditure, and promotes lipolysis. This dual mechanism is particularly effective for MASH, where hepatic fat accumulation is the core pathology. Unlike tirzepatide (which targets GIP/GLP-1), survodutide targets glucagon/GLP-1 — a different receptor combination optimized for liver and metabolic outcomes. |
| Typical Dosage | Medical: 0.1-0.3mg/kg/week divided into daily doses. Anti-aging: 1-2 IU daily. Performance: 2-6 IU daily, sometimes higher. | Phase 2 MASH trial: escalated to 2.4 mg, 4.8 mg, or 6.0 mg weekly. Phase 2b obesity trial: up to 6.0 mg weekly. Dose escalation over 16-20 weeks to manage GI tolerability. Final approved dosing not yet established — Phase 3 trials ongoing. |
| Administration | Subcutaneous injection, preferably at night to mimic natural pulsatile release. Rotate injection sites. Store refrigerated. | Subcutaneous injection, once weekly. Phase 3 trials use pre-filled pens. Not yet commercially available. Phase 3 results expected 2026-2027. |
| Side Effects | Joint pain, water retention, carpal tunnel syndrome, potential insulin resistance, and acromegaly features with long-term high doses. | Phase 2 data: nausea, vomiting, diarrhea (dose-dependent, generally transient). Reduced appetite. Transient increases in heart rate. The GI side effect profile appears similar to other GLP-1 agonists. |
| Best For |
Key Differences
Unique to Human Growth Hormone (HGH):
Unique to Survodutide:
Detailed Analysis
Commonalities
Human Growth Hormone (HGH) and Survodutide are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose Human Growth Hormone (HGH) for Muscle Growth, Fat Loss, Recovery & Healing, Sleep Quality, Anti-Aging & Longevity. Choose Survodutide for Weight Loss, Liver Health.
Ready to Learn More?
Looking for trusted sources?